These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 21543655

  • 1. Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation.
    Herrmann SM, Gertz MA, Stegall MD, Dispenzieri A, Cosio FC, Kumar S, Lacy MQ, Dean PG, Prieto M, Zeldenrust SR, Buadi FK, Russell SJ, Nyberg SL, Hayman SR, Dingli D, Fervenza FC, Leung N.
    Nephrol Dial Transplant; 2011 Jun; 26(6):2032-6. PubMed ID: 21543655
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
    Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.
    Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
    [Abstract] [Full Text] [Related]

  • 3. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome.
    Bergesio F, Ciciani AM, Manganaro M, Palladini G, Santostefano M, Brugnano R, Di Palma AM, Gallo M, Rosati A, Tosi PL, Salvadori M, Immunopathology Group of the Italian Society of Nephrology.
    Nephrol Dial Transplant; 2008 Mar; 23(3):941-51. PubMed ID: 17951308
    [Abstract] [Full Text] [Related]

  • 4. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Severity of baseline proteinuria predicts renal response in immunoglobulin light chain-associated amyloidosis after autologous stem cell transplantation.
    Leung N, Dispenzieri A, Lacy MQ, Kumar SK, Hayman SR, Fervenza FC, Cha SS, Gertz MA.
    Clin J Am Soc Nephrol; 2007 May; 2(3):440-4. PubMed ID: 17699449
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term results of a risk-adapted approach to melphalan conditioning in autologous peripheral blood stem cell transplantation for primary (AL) amyloidosis.
    Perfetti V, Siena S, Palladini G, Bregni M, Di Nicola M, Obici L, Magni M, Brunetti L, Gianni AM, Merlini G.
    Haematologica; 2006 Dec; 91(12):1635-43. PubMed ID: 17145600
    [Abstract] [Full Text] [Related]

  • 10. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.
    Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
    [Abstract] [Full Text] [Related]

  • 11. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP, Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.
    N Engl J Med; 2007 Sep 13; 357(11):1083-93. PubMed ID: 17855669
    [Abstract] [Full Text] [Related]

  • 12. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients.
    Terpos E, Apperley JF, Samson D, Giles C, Crawley C, Kanfer E, Olavarria E, Goldman JM, Rahemtulla A.
    Bone Marrow Transplant; 2003 Feb 13; 31(3):163-70. PubMed ID: 12621476
    [Abstract] [Full Text] [Related]

  • 13. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA.
    Bone Marrow Transplant; 2005 Oct 13; 36(7):591-6. PubMed ID: 16062177
    [Abstract] [Full Text] [Related]

  • 14. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney.
    Eirin A, Irazabal MV, Gertz MA, Dispenzieri A, Lacy MQ, Kumar S, Sethi S, Nasr SH, Cornell LD, Fidler ME, Fervenza FC, Leung N.
    Nephrol Dial Transplant; 2012 Mar 13; 27(3):1097-101. PubMed ID: 22067518
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct 13; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 17. Autologous stem cell transplantation in light-chain amyloidosis patients: a single-center experience in Korea.
    Kim SJ, Lee GY, Jang HR, Choi JO, Kim JS, Kim HJ, Lee SY, Min JH, Jeon ES, Kim K.
    Amyloid; 2013 Dec 13; 20(4):204-11. PubMed ID: 23914780
    [Abstract] [Full Text] [Related]

  • 18. [Completely reversed acute rejection episodes do not influence the long-term renal allograft survival].
    Wu JY, Chen JH, Wang YM, Zhang JG, Zhu C, Wang SY, Zhang P, Huang HF, He Q.
    Zhonghua Yi Xue Za Zhi; 2003 Jan 25; 83(2):106-9. PubMed ID: 12812676
    [Abstract] [Full Text] [Related]

  • 19. Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome.
    Mollee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C, Stewart AK.
    Bone Marrow Transplant; 2004 Feb 25; 33(3):271-7. PubMed ID: 14647248
    [Abstract] [Full Text] [Related]

  • 20. A multicenter phase 2 trial of stem cell transplantation for immunoglobulin light-chain amyloidosis (E4A97): an Eastern Cooperative Oncology Group Study.
    Gertz MA, Blood E, Vesole DH, Abonour R, Lazarus HM, Greipp PR.
    Bone Marrow Transplant; 2004 Jul 25; 34(2):149-54. PubMed ID: 15156165
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.